🟢 Mirum Pharmaceuticals is trading 4.41% up on November 4, 2026, after Q3 revenue beat estimates and guidance rose

Mirum Pharmaceuticals is trading at $90.87, up 4.41%, after third-quarter revenue beat estimates and management raised 2026 product-sales guidance.

• Third-quarter revenue was $185.7 million, up 40% year over year; 2026 product-sales guidance rose to $715 million–$720 million.
• Raymond James raised its target to $189 from $183, citing commercial strength after the results; the report also showed a wider-than-expected loss.
• Biotech and major indexes were higher, potentially adding support; live volume was not provided.